Compare Genuine Parts Company (GPC) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Inovio Pharmaceuticals Inc — how do they compare? Genuine Parts Company trades at $127.02 (market cap $17.67B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Genuine Parts Company is far larger — about 157.5× Inovio Pharmaceuticals Inc's market cap, and Genuine Parts Company pays a 3.32% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| GPC | INO | |
|---|---|---|
Market Cap | $17.67B | $112.19M |
Volume | 1,079,458 | 3,201,278 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $2.60 |
52-Week Low | $92.47 | $0.66 |
Typical Hold Time | 75 Days | 43 Days |
Enterprise Value | $23.76B | $83.51M |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $128.17, up 2.2% on the day, with a bullish technical signal and support near $125. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, while revenue grew to $24.3B in 2025. Analyst consensus is a Buy with a $145.75 price target, and the upcoming corporate split into automotive and industrial units in Q1 2027 is a key catalyst.
The outlook is positive due to the spinoff potential and steady dividend, but risks include thin net margins of 0.13% and rising debt-to-asset ratios. Investors should weigh the bullish analyst sentiment against profitability challenges and execution risks from the separation.
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
